OncoMatch/Clinical Trials/NCT07081633

Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma

Is NCT07081633 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Durvalumab and Tremelimumab for hepatocellular carcinoma.

Phase 2RecruitingAstraZenecaNCT07081633Data as of May 2026

Treatment: Durvalumab · Tremelimumab · Lenvatinib — This is a Phase II, single-arm, multicentre study, assessing the efficacy and safety of durvalumab and tremelimumab with lenvatinib in participants with unresectable HCC.

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Disease stage

Required: Stage BCLC STAGE B (NOT ELIGIBLE FOR LOCOREGIONAL THERAPY), BCLC STAGE C (BCLC)

Barcelona Clinic Liver Cancer (BCLC) stage B (that is not eligible for locoregional therapy) or stage C

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Liver function

child-pugh score class a

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify